VRNA

AcronymDefinition
VRNAVentana Ranch Neighborhood Association (est. 2001; Albuquerque, NM)
VRNAVeterans Resource Network Association
VRNAViral Ribonucleic Acid
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Additional studies, such as examination of the crystal structures of the full RIG-I/MDA5 proteins bound to vRNA, are required to understand the fine molecular mechanisms related to the vRNA and the sensor structural properties, in order to have one unifying and comprehensive theory.
With this method, we revealed that the cRNA of NDV accumulated faster than its vRNA. The development of this assay will be helpful for further studies on the pathogenesis and control strategies of NDV.
suggested that human hvg1 and hvg2 vRNA can bind the anticancer drug mitoxantrone and may play an important role in exporting toxic compounds.
In the randomized, phase IV study of 282 patients who had viral RNA (vRNA) less than 50 copies/mL at weeks 36 and 44 of the 48-week induction phase, 141 were maintained on Trizivir (GlaxoSmithKline), and 141 continued to receive the Trizivir plus efavirenz (Sustiva, Bristol-Myers Squibb) combination.
An important part of the system is the easy-to-use NAT-Q vRNA V1.0 and Gemini V3.2 software.
Release date- 06082019 - LONDON - Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ('Verona Pharma' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces an operational update and financial results for the three months and six months ended June 30, 2019.
London-based biopharma firm Verona Pharma plc (LON: VRP) (NASDAQ: VRNA) announced on Monday that it had begun the clinical pharmacokinetic trial for its product candidate RPL554.
Distinct regions of influenza virus PB1 polymerase subunit recognize vRNA and cRNA templates.
7) Nucleoproteins (NPs) needed for viral replication are associated with vRNA molecules.
Release date- 05082019 - LONDON - Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ('Verona Pharma'), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler ('DPI') formulation of its lead development product, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease ('COPD').
Viral RNA (vRNA) was extracted from each of the thawed nasopharyngeal swabs with the QIAamp viral RNA minikit (QIAGEN Inc., Valencia, CA, USA) according to the manufacturer's instructions.